Researchers have revealed how Staphylococcus aureus bacteria extract iron from hemoglobin—a process crucial to their survival ...
Researchers at The Wistar Institute's HIV Cure and Viral Diseases Center have successfully identified a new approach using ...
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...
Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...
Lonza Group AG has selected Bank of America Corp. and Centerview Partners to arrange the sale of its capsules and health ...
In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about the challenges faced in developing T cell engagers.
The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...
A study published in December by Duke professor Rohit Singh and his team proposes a new computational model called antibody ...
Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.
If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...
In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering.
The bacteria Campylobacter jejuni has been found in 20-30 per cent of the samples taken from those patients who tested ...